APA (7th ed.) Citation

Berrada, M., Kolenda, C., Tristan, A., Laurent, F., & Dupieux, C. (2026). Could oritavancin be a promising alternative treatment for staphylococcal bone and joint infections? Insights from the determination of oritavancin minimum inhibitory concentrations in a collection of clinical isolates from the French National reference centre for staphylococci. European Journal of Clinical Microbiology & Infectious Diseases, 45(5), 1477. https://doi.org/10.1007/s10096-025-05383-3

Chicago Style (17th ed.) Citation

Berrada, M., C. Kolenda, A. Tristan, F. Laurent, and C. Dupieux. "Could Oritavancin Be a Promising Alternative Treatment for Staphylococcal Bone and Joint Infections? Insights from the Determination of Oritavancin Minimum Inhibitory Concentrations in a Collection of Clinical Isolates from the French National Reference Centre for Staphylococci." European Journal of Clinical Microbiology & Infectious Diseases 45, no. 5 (2026): 1477. https://doi.org/10.1007/s10096-025-05383-3.

MLA (9th ed.) Citation

Berrada, M., et al. "Could Oritavancin Be a Promising Alternative Treatment for Staphylococcal Bone and Joint Infections? Insights from the Determination of Oritavancin Minimum Inhibitory Concentrations in a Collection of Clinical Isolates from the French National Reference Centre for Staphylococci." European Journal of Clinical Microbiology & Infectious Diseases, vol. 45, no. 5, 2026, p. 1477, https://doi.org/10.1007/s10096-025-05383-3.